{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T21:29:31Z","timestamp":1790026171383,"version":"4.0.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jdcjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.jdiacomp.2016.01.016","type":"journal-article","created":{"date-parts":[[2016,1,23]],"date-time":"2016-01-23T02:14:27Z","timestamp":1453515267000},"page":"675-680","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Oral antidiabetics use among diabetic type 2 patients with chronic kidney disease. Do nephrologists take account of recommendations?"],"prefix":"10.1016","volume":"30","author":[{"given":"Clotilde","family":"Muller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Dimitrov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Imhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7387-5738","authenticated-orcid":false,"given":"Julien","family":"Ott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Krummel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doroth\u00e9e","family":"Bazin-Kara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Chantrel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Hannedouche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2016.01.016_bb0085","author":"Anonymous"},{"issue":"1","key":"10.1016\/j.jdiacomp.2016.01.016_bb0245","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/1753-0407.12257","article-title":"Specialist-led diabetes registries and predictors of poor glycemic control in type 2 diabetes: Insights into the functionally refractory patient from the LMC Diabetes Registry database","volume":"8","author":"Aronson","year":"2015","journal-title":"Journal of Diabetes"},{"issue":"Suppl. 2","key":"10.1016\/j.jdiacomp.2016.01.016_bb0080","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S1262-3636(11)70961-2","article-title":"Expert consensus on management of diabetic patients with impairment of renal function","volume":"37","author":"Bonnet","year":"2011","journal-title":"Diabetes & Metabolism"},{"issue":"7","key":"10.1016\/j.jdiacomp.2016.01.016_bb0205","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1463-1326.2008.00914.x","article-title":"Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency","volume":"10","author":"Chan","year":"2008","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"3","key":"10.1016\/j.jdiacomp.2016.01.016_bb0060","doi-asserted-by":"crossref","first-page":"221","DOI":"10.4158\/EP13269.OR","article-title":"Outcomes associated with nonconcordance to national kidney foundation guideline recommendations for oral antidiabetic drug treatments in patients with concomitant type 2 diabetes and chronic kidney disease","volume":"20","author":"Chen","year":"2014","journal-title":"Endocrine Practice"},{"issue":"2","key":"10.1016\/j.jdiacomp.2016.01.016_bb0070","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.diabet.2011.11.005","article-title":"Chronic kidney disease in type 2 diabetes patients in France: Prevalence, influence of glycaemic control and implications for the pharmacological management of diabetes","volume":"38","author":"Detournay","year":"2012","journal-title":"Diabetes & Metabolism"},{"issue":"8","key":"10.1016\/j.jdiacomp.2016.01.016_bb0195","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/j.1463-1326.2012.01591.x","article-title":"Glucose-lowering treatment and clinical results in 163 121 patients with type 2 diabetes: An observational study from the Swedish national diabetes register","volume":"14","author":"Ekstr\u00f6m","year":"2012","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"1","key":"10.1016\/j.jdiacomp.2016.01.016_bb0045","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1053\/j.ajkd.2013.03.015","article-title":"Performance of GFR estimating equations in African Europeans: Basis for a lower race\u2013ethnicity factor than in African Americans","volume":"62","author":"Flamant","year":"2013","journal-title":"American Journal of Kidney Diseases"},{"issue":"Suppl. 2","key":"10.1016\/j.jdiacomp.2016.01.016_bb0025","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1093\/ndt\/gfv100","article-title":"Clinical practice guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR)","volume":"30","author":"Guideline development group","year":"2015","journal-title":"Nephrology, Dialysis, Transplantation"},{"issue":"3","key":"10.1016\/j.jdiacomp.2016.01.016_bb0125","doi-asserted-by":"crossref","first-page":"886","DOI":"10.2337\/diacare.26.3.886","article-title":"Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function","volume":"26","author":"Hasslacher","year":"2003","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.jdiacomp.2016.01.016_bb0105","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2013.06.020","article-title":"Glycated hemoglobin and risk of death in diabetic patients treated with hemodialysis: A meta-analysis","volume":"63","author":"Hill","year":"2014","journal-title":"American Journal of Kidney Diseases"},{"issue":"8","key":"10.1016\/j.jdiacomp.2016.01.016_bb0185","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1046\/j.1464-5491.1999.00115.x","article-title":"Contra-indications to metformin therapy are largely disregarded","volume":"16","author":"Holstein","year":"1999","journal-title":"Diabetic Medicine"},{"issue":"12","key":"10.1016\/j.jdiacomp.2016.01.016_bb0170","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1007\/s00125-005-0026-1","article-title":"Contraindications can damage your health\u2014Is metformin a case in point?","volume":"48","author":"Holstein","year":"2005","journal-title":"Diabetologia"},{"issue":"8","key":"10.1016\/j.jdiacomp.2016.01.016_bb0175","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(15)00123-0","article-title":"Metformin use and mortality in patients with advanced chronic kidney disease: National, retrospective, observational, cohort study","volume":"3","author":"Hung","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7379","key":"10.1016\/j.jdiacomp.2016.01.016_bb0190","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/bmj.326.7379.4","article-title":"Contraindications to the use of metformin","volume":"326","author":"Jones","year":"2003","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.jdiacomp.2016.01.016_bb0010","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1002\/pds.3501","article-title":"Metformin therapy and kidney disease: A review of guidelines and proposals for metformin withdrawal around the world","volume":"22","author":"Kajbaf","year":"2013","journal-title":"Pharmacoepidemiology and Drug Safety"},{"issue":"11","key":"10.1016\/j.jdiacomp.2016.01.016_bb0005","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1016\/j.clinthera.2009.10.020","article-title":"Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States","volume":"31","author":"Koro","year":"2009","journal-title":"Clinical Therapeutics"},{"issue":"3","key":"10.1016\/j.jdiacomp.2016.01.016_bb0120","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S0272-6386(00)70204-6","article-title":"Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end-stage renal disease","volume":"35","author":"Krepinsky","year":"2000","journal-title":"American Journal of Kidney Diseases"},{"issue":"2","key":"10.1016\/j.jdiacomp.2016.01.016_bb0100","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/ki.2014.19","article-title":"Metformin and other antidiabetic agents in renal failure patients","volume":"87","author":"Lalau","year":"2015","journal-title":"Kidney International"},{"key":"10.1016\/j.jdiacomp.2016.01.016_bb0030","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/0003-4819-139-2-200307150-00013","article-title":"National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification","author":"Levey","year":"2003","journal-title":"Annals of Internal Medicine"},{"issue":"9","key":"10.1016\/j.jdiacomp.2016.01.016_bb0040","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Annals of Internal Medicine"},{"issue":"4 Pt 2","key":"10.1016\/j.jdiacomp.2016.01.016_bb0150","article-title":"Metformin and vascular protection: A cardiologist's view","volume":"29","author":"Libby","year":"2003","journal-title":"Diabetes & Metabolism"},{"issue":"10","key":"10.1016\/j.jdiacomp.2016.01.016_bb0215","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/j.1463-1326.2011.01467.x","article-title":"Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: A prospective 24-week randomized placebo-controlled trial","volume":"13","author":"Lukashevich","year":"2011","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"4","key":"10.1016\/j.jdiacomp.2016.01.016_bb0095","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1159\/000186953","article-title":"Glucose and insulin metabolism in uremia","volume":"61","author":"Mak","year":"1992","journal-title":"Nephron"},{"issue":"1","key":"10.1016\/j.jdiacomp.2016.01.016_bb0130","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1067\/mcp.2000.103973","article-title":"Pharmacokinetics of repaglinide in subjects with renal impairment","volume":"67","author":"Marbury","year":"2000","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.jdiacomp.2016.01.016_bb0015","series-title":"Drug dosing consideration in patients with acute and chronic kidney disease\u2014A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)","first-page":"1122","author":"Matzke","year":"2011"},{"issue":"5","key":"10.1016\/j.jdiacomp.2016.01.016_bb0180","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1503\/cmaj.045292","article-title":"Metformin's contraindications should be contraindicated","volume":"173","author":"McCormack","year":"2005","journal-title":"CMAJ"},{"issue":"2","key":"10.1016\/j.jdiacomp.2016.01.016_bb0210","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2337\/dc12-0706","article-title":"Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: A 1-year, randomized, double-blind, placebo-controlled study","volume":"36","author":"McGill","year":"2013","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.jdiacomp.2016.01.016_bb0055","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.2215\/CJN.06870909","article-title":"Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size","volume":"5","author":"Michels","year":"2010","journal-title":"Clinical Journal of the American Society of Nephrology"},{"key":"10.1016\/j.jdiacomp.2016.01.016_bb0075","author":"National Kidney Disease Education Program"},{"key":"10.1016\/j.jdiacomp.2016.01.016_bb0035","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification","author":"National Kidney Foundation","year":"2002","journal-title":"American journal of kidney diseases: The official journal of the National Kidney Foundation"},{"issue":"4","key":"10.1016\/j.jdiacomp.2016.01.016_bb0240","doi-asserted-by":"crossref","first-page":"260","DOI":"10.5414\/CNP73260","article-title":"Referral patterns of primary care physicians for chronic kidney disease in general population and geriatric patients","volume":"73","author":"Navaneethan","year":"2010","journal-title":"Clinical Nephrology"},{"issue":"6","key":"10.1016\/j.jdiacomp.2016.01.016_bb0220","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1463-1326.2011.01382.x","article-title":"Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment","volume":"13","author":"Nowicki","year":"2011","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"12","key":"10.1016\/j.jdiacomp.2016.01.016_bb0225","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/j.1742-1241.2011.02812.x","article-title":"Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: A randomised controlled 52-week efficacy and safety study","volume":"65","author":"Nowicki","year":"2011","journal-title":"International Journal of Clinical Practice"},{"issue":"4","key":"10.1016\/j.jdiacomp.2016.01.016_bb0165","doi-asserted-by":"crossref","first-page":"c380","DOI":"10.1159\/000323739","article-title":"Metformin: The safest hypoglycaemic agent in chronic kidney disease?","volume":"118","author":"Nye","year":"2011","journal-title":"Nephron. Clinical Practice"},{"key":"10.1016\/j.jdiacomp.2016.01.016_bb0020","first-page":"341","article-title":"How are patients with type 2 diabetes and renal disease monitored and managed? Insights from the observational OREDIA study","volume":"10","author":"Penfornis","year":"2014","journal-title":"Vascular Health and Risk Management"},{"issue":"7","key":"10.1016\/j.jdiacomp.2016.01.016_bb0200","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/dme.12709","article-title":"Use of metformin in chronic kidney disease should continue to be based on common sense in the absence of an evidence base","volume":"32","author":"Petrie","year":"2015","journal-title":"Diabetic Medicine"},{"issue":"5","key":"10.1016\/j.jdiacomp.2016.01.016_bb0090","doi-asserted-by":"crossref","first-page":"886","DOI":"10.2337\/diacare.24.5.886","article-title":"Impact of diabetic nephropathy on pharmacodynamic and pharmacokinetic properties of insulin in type 1 diabetic patients","volume":"24","author":"Rave","year":"2001","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.jdiacomp.2016.01.016_bb0115","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1007\/s001250050624","article-title":"Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment","volume":"39","author":"Rosenkranz","year":"1996","journal-title":"Diabetologia"},{"issue":"21","key":"10.1016\/j.jdiacomp.2016.01.016_bb0145","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1001\/archinternmed.2010.409","article-title":"Metformin use and mortality among patients with diabetes and atherothrombosis","volume":"170","author":"Roussel","year":"2010","journal-title":"Archives of Internal Medicine"},{"issue":"2","key":"10.1016\/j.jdiacomp.2016.01.016_bb0135","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s002280100280","article-title":"Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment","volume":"57","author":"Schumacher","year":"2001","journal-title":"European Journal of Clinical Pharmacology"},{"key":"10.1016\/j.jdiacomp.2016.01.016_bb0235","first-page":"CD007333","article-title":"Early referral to specialist nephrology services for preventing the progression to end-stage kidney disease","volume":"6","author":"Smart","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1016\/j.jdiacomp.2016.01.016_bb0065","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/jgs.12381","article-title":"Age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment in type 2 diabetes mellitus: Findings from the Renal Insufficiency and Cardiovascular Events Italian Multicenter Study","volume":"61","author":"Solini","year":"2013","journal-title":"Journal of American Geriatrics Society"},{"issue":"1","key":"10.1016\/j.jdiacomp.2016.01.016_bb0050","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1053\/j.ajkd.2009.03.008","article-title":"Comparison of drug dosing recommendations based on measured GFR and kidney function estimating equations","volume":"54","author":"Stevens","year":"2009","journal-title":"American Journal of Kidney Diseases"},{"issue":"9131","key":"10.1016\/j.jdiacomp.2016.01.016_bb0140","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"issue":"12 Suppl.","key":"10.1016\/j.jdiacomp.2016.01.016_bb0230","first-page":"S55","article-title":"End-stage renal disease treatment: A European perspective","volume":"9","author":"Van Biesen","year":"1998","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1016\/j.jdiacomp.2016.01.016_bb0110","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1093\/ndt\/gfq649","article-title":"Impaired renal function modifies the risk of severe hypoglycaemia among users of insulin but not glyburide: A population-based nested case\u2013control study","volume":"26","author":"Weir","year":"2011","journal-title":"Nephrology, Dialysis, Transplantation"},{"issue":"1","key":"10.1016\/j.jdiacomp.2016.01.016_bb0155","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s10557-012-6425-x","article-title":"Chronic metformin associated cardioprotection against infarction: Not just a glucose lowering phenomenon","volume":"27","author":"Whittington","year":"2013","journal-title":"Cardiovascular Drugs and Therapy"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872716000180?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872716000180?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T08:55:26Z","timestamp":1600073726000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872716000180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S1056872716000180"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2016.01.016","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral antidiabetics use among diabetic type 2 patients with chronic kidney disease. Do nephrologists take account of recommendations?","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2016.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}